Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.68 |
| ▸ | ESR1 | P03372 | 2/20 | 0.68 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.54 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1265874 | 0.94 | ESR1 (0.59) | ESR2ESR1AKR1C3KDM2BHRH3 | |
| SCHEMBL23589286 | 0.86 | HDAC1 (0.51) | ESR2ESR1AKR1C3HRH3HSD17B3 | |
| SCHEMBL38665856 | 0.85 | AKR1C3 (0.55) | ESR2ESR1AKR1C3HSD17B3CARM1 | |
| SCHEMBL22504152 | 0.85 | AKR1C3 (0.55) | ESR2ESR1AKR1C3HSD17B3CARM1 | |
| SCHEMBL13102503 | 0.82 | ESR2 (0.69) | ESR2ESR1AKR1C3KDM2BHRH3 | |
| SCHEMBL22469099 | 0.82 | ESR1 (0.54) | ESR2ESR1AKR1C3KDM2BHRH3 | |
| SCHEMBL31287276 | 0.82 | ESR1 (0.54) | ESR2ESR1AKR1C3KDM2BHRH3 | |
| SCHEMBL3185585 | 0.81 | ESR2 (0.68) | ESR2ESR1AKR1C3KDM2BHRH3 | |
| SCHEMBL3178018 | 0.81 | ESR2 (1.00) | ESR2ESR1AKR1C3KDM2BHRH3 | |
| SCHEMBL14116840 | 0.81 | ESR2 (0.68) | ESR2ESR1AKR1C3KDM2BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| EP-2114890-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008097428-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GCGR, GPR65 | ESR2 218/4885ESR1 638/4885AKR1C3 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.